Los Angeles, CA -- (SBWIRE) -- 04/10/2019 -- Chemotherapy-induced nausea and vomiting (CINV) is a common side-effect of many cancer treatments. Nausea and vomiting are two of the most feared cancer treatment-related side effects for cancer patients and their families.
The classification of Chemotherapy Induced Nausea and Vomiting (CINV) Drugs includes 5-HT3 Inhibitors, NK1 Inhibitors and others. The proportion of 5-HT3 Inhibitors in 2017 is about 62%, and the proportion of NK1 Inhibitors in 2017 is about 33%.
Chemotherapy Induced Nausea and Vomiting (CINV) Drugs are application for Highly Emetogenic Chemotherapy, Moderately Emetogenic Chemotherapy, Low Emetogenic Chemotherapy and others. The most of Chemotherapy Induced Nausea and Vomiting (CINV) Drugs is used for Moderately Emetogenic Chemotherapy, and the market share of that is about 52 % in 2017.
Get PDF template of this report: https://www.qyresearch.com/sample-form/form/1076688/global-chemotherapy-induced-nausea-and-vomiting-cinv-drugs-market
The global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs market was 72 million US$ in 2018 and is expected to 110 million US$ by the end of 2025, growing at a CAGR of 6.1% between 2019 and 2025.
This report studies the Chemotherapy Induced Nausea and Vomiting (CINV) Drugs market size (value and volume) by players, regions, product types and end industries, history data 2014-2018 and forecast data 2019-2025; This report also studies the global market competition landscape, market drivers and trends, opportunities and challenges, risks and entry barriers, sales channels, distributors and Porter's Five Forces Analysis.
Geographically, this report is segmented into several key regions, with sales, revenue, market share and growth Rate of Chemotherapy Induced Nausea and Vomiting (CINV) Drugs in these regions, from 2014 to 2025, covering
North America (United States, Canada and Mexico)
Europe (Germany, UK, France, Italy, Russia and Turkey etc.)
Asia-Pacific (China, Japan, Korea, India, Australia, Indonesia, Thailand, Philippines, Malaysia and Vietnam)
South America (Brazil etc.)
Middle East and Africa (Egypt and GCC Countries)
The various contributors involved in the value chain of the product include manufacturers, suppliers, distributors, intermediaries, and customers. The key manufacturers in this market include
Merck
Eisai
Mundipharma
Qilu Pharma
Teva
Novartis
Heron Therapeutics
Roche
Mylan
Tesaro
By the product type, the market is primarily split into
5-HT3 Inhibitors
NK1 Inhibitors
Other
By the end users/application, this report covers the following segments
Highly Emetogenic Chemotherapy
Moderately Emetogenic Chemotherapy
Low Emetogenic Chemotherapy
Other
We can also provide the customized separate regional or country-level reports, for the following regions:
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Rest of Asia-Pacific
Europe
Germany
France
UK
Italy
Spain
Russia
Rest of Europe
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa
Rest of Middle East & Africa
Get Full Report Now at USD 3,550 @ https://www.qyresearch.com/login?product_ids=9582a53dc1657c88a822e1c2e8043d05&product_title=Global%20Chemotherapy%20Induced%20Nausea%20and%20Vomiting%20(CINV)%20Drugs%20Market%20Report,%20History%20and%20Forecast%202014-2025,%20Breakdown%20Data%20by%20Manufacturers,%20Key%20Regions,%20Types%20and%20Application&product_pages=129&product_table=166&product_date=2019-04-05&price=3350.00&pricetype=singleprise
About QYResearch
QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from the huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in the consulting industry.